Liminatus Pharma Faces Delisting Notice
Ticker: LIMNW · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1971387
| Field | Detail |
|---|---|
| Company | Liminatus Pharma, Inc. (LIMNW) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory-filing
TL;DR
Liminatus Pharma's stock is at risk of being delisted due to failing to meet listing rules.
AI Summary
Liminatus Pharma, Inc. filed an 8-K on August 25, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, previously known as Iris Parent Holding Corp. until March 28, 2023, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential issues with Liminatus Pharma's compliance with stock exchange listing standards, which could lead to its shares being delisted.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that directly impacts the stock's tradability and the company's viability.
Key Numbers
- 001-42626 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Liminatus Pharma, Inc. (company) — Registrant
- Iris Parent Holding Corp. (company) — Former Company Name
- 20250825 (date) — Filing Date
- 20250822 (date) — Earliest Event Date
- 001-42626 (company) — SEC File Number
FAQ
What specific listing rule or standard has Liminatus Pharma, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Liminatus Pharma, Inc. has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 22, 2025.
When was Liminatus Pharma, Inc. previously known by another name?
Liminatus Pharma, Inc. was formerly known as Iris Parent Holding Corp. until March 28, 2023.
In which state is Liminatus Pharma, Inc. incorporated?
Liminatus Pharma, Inc. is incorporated in Delaware.
What is the business address of Liminatus Pharma, Inc.?
The business address is 6 Centerpointe Drive, #625, La Palma, CA 90623.
Filing Stats: 813 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2025-08-25 17:15:38
Filing Documents
- tm2524293d1_8k.htm (8-K) — 31KB
- tm2524293d1_ex99-7.htm (EX-99.7) — 7KB
- 0001104659-25-082579.txt ( ) — 245KB
- limn-20250822.xsd (EX-101.SCH) — 3KB
- limn-20250822_def.xml (EX-101.DEF) — 26KB
- limn-20250822_lab.xml (EX-101.LAB) — 36KB
- limn-20250822_pre.xml (EX-101.PRE) — 25KB
- tm2524293d1_8k_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 22, 2025, Liminatus Pharma, Inc. (the "Company") received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the "Form 10-Q"). The deficiency letter has no immediate effect on the listing of the Company's common stock, and its common stock will continue to trade on Nasdaq under the symbol "LIMN" at this time. Under the Nasdaq rules, the Company has 60 calendar days, or until October 21, 2025, to submit a plan to regain compliance and if the plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until February 16, 2026, to regain compliance. If the compliance plan is not accepted, the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Company is in the process of completing the Form 10-Q and intends to file it as soon as practicable. As required under Nasdaq Listing Rule 5810(b), on August 25, 2025, the Company issued a press release announcing its receipt of the non-compliance notice. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Forward-Looking Statements
Forward-Looking Statements Certain information contained in this report consists of forward-looking Words such as "will," "would," "may," "intends," "potential," and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will regain compliance with the Nasdaq listing rules during any compliance period or in the future, or otherwise meet Nasdaq continued listing standards. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's filings with the SEC. The forward-looking any forward-looking statements to reflect changes in information, events or circumstances after the date of this report, unless required by law.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.7 Press Release, dated August 25, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 25, 2025 LIMINATUS PHARMA, INC. By: /s/ Chris Kim Name: Chris Kim Title: Chief Executive Officer